Condition: Cardiac Sarcoidosis · Sponsor: Mayo Clinic
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
This description comes directly from the study's public registry record.
Lezlie Peterson, R.N. · 507-255-2029 · Johnson.Lezlie@mayo.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06660732